Is the NHS ready for Alzheimer’s drug breakthroughs?
Newscast
00:00
Breakthrough Alzheimer's Drugs: Impact and Concerns
This chapter discusses the emotional and practical impact of breakthrough Alzheimer's drugs, Lacanamab and Dananamab, which have shown to slow cognitive decline and provide patients with more time. It also raises concerns about potential side effects, limited access to diagnostic methods, and the challenges of accessing the drugs once licensed. The chapter explores the cost, licensing, and potential impact on healthcare systems, as well as the importance of early diagnosis and investment in dementia research.
Transcript
Play full episode
